Cited 104 times in
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박미숙 | - |
dc.contributor.author | 백용한 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 유정식 | - |
dc.contributor.author | 윤동섭 | - |
dc.contributor.author | 이동기 | - |
dc.contributor.author | 이세준 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 정재복 | - |
dc.contributor.author | 조재용 | - |
dc.contributor.author | 장윤수 | - |
dc.date.accessioned | 2017-10-26T06:44:32Z | - |
dc.date.available | 2017-10-26T06:44:32Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 0008-543X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/151239 | - |
dc.description.abstract | BACKGROUND: Biliary tract carcinoma is an aggressive cancer, with median survival rarely exceeding 6 months. There is currently no established palliative standard of care. A Phase II trial was conducted to study a combination of oral capecitabine and gemcitabine (CapGem) as first-line therapy in patients with advanced and/or metastatic biliary carcinoma. METHODS: Patients with unresectable or metastatic intrahepatic or extrahepatic biliary duct carcinoma and gallbladder carcinoma were enrolled. Eligible patients had histologically or cytologically confirmed, measurable adenocarcinoma and had not received prior therapy with capecitabine or gemcitabine. Treatment consisted of intravenous (i.v.) gemcitabine (1000 mg/m(2) on Days 1 and 8) plus oral capecitabine (650 mg/m(2) twice daily on Days 1-14) every 3 weeks for up to 6 cycles. Tumor response, survival, and safety were determined. RESULTS: A total of 44 patients were evaluable. Primary tumor sites were: intrahepatic (n = 14) and extrahepatic biliary duct (n = 16); gallbladder (n = 7); and ampulla (n = 7). Fourteen (32%) patients had a partial response and 15 (34%) patients had stable disease. Median time to disease progression and overall survival were 6.0 (range, 3.8-8.1) and 14 (range, 11.4-16.6) months, respectively. The 1-year survival rate was 58%. No Grade 4 adverse events were seen. Transient Grade 3 neutropenia/thrombocytopenia and manageable (almost invariably Grade 2) nausea, diarrhea, and hand-foot syndrome were the most common adverse events. CONCLUSIONS: CapGem is an active and well tolerated first-line combination chemotherapy regimen for patients with advanced/metastatic biliary tract carcinoma that offers a convenient home-based therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley | - |
dc.relation.isPartOf | CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Biliary Tract Neoplasms/drug therapy* | - |
dc.subject.MESH | Biliary Tract Neoplasms/mortality | - |
dc.subject.MESH | Biliary Tract Neoplasms/pathology | - |
dc.subject.MESH | Biopsy, Needle | - |
dc.subject.MESH | Bone Neoplasms/secondary | - |
dc.subject.MESH | Capecitabine | - |
dc.subject.MESH | Carcinoma, Ductal/drug therapy* | - |
dc.subject.MESH | Carcinoma, Ductal/secondary* | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/analogs & derivatives | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunohistochemistry | - |
dc.subject.MESH | Liver Neoplasms/secondary | - |
dc.subject.MESH | Lung Neoplasms/secondary | - |
dc.subject.MESH | Lymphatic Metastasis | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Maximum Tolerated Dose | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiology (영상의학교실) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.department | Dept. of Radiology (영상의학교실) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.contributor.googleauthor | Yong Han Paik | - |
dc.contributor.googleauthor | Yoon Soo Chang | - |
dc.contributor.googleauthor | Se Joon Lee | - |
dc.contributor.googleauthor | Dong-Ki Lee | - |
dc.contributor.googleauthor | Si Young Song | - |
dc.contributor.googleauthor | Jae Bock Chung | - |
dc.contributor.googleauthor | Mi-Suk Park | - |
dc.contributor.googleauthor | Jeong-Sik Yu | - |
dc.contributor.googleauthor | Dong-Sup Yoon | - |
dc.identifier.doi | 10.1002/cncr.21591 | - |
dc.contributor.localId | A01463 | - |
dc.contributor.localId | A01829 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A02500 | - |
dc.contributor.localId | A02548 | - |
dc.contributor.localId | A02723 | - |
dc.contributor.localId | A02882 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A03706 | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J00434 | - |
dc.identifier.eissn | 1097-0142 | - |
dc.identifier.pmid | 16294346 | - |
dc.subject.keyword | biliary tract carcinoma | - |
dc.subject.keyword | Phase II trial | - |
dc.subject.keyword | capecitabine | - |
dc.subject.keyword | gemcitabine | - |
dc.contributor.alternativeName | Park, Mi Sook | - |
dc.contributor.alternativeName | Park, Mi Sook | - |
dc.contributor.alternativeName | Paik, Yong Han | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.alternativeName | Yu, Jeong Sik | - |
dc.contributor.alternativeName | Yoon, Dong Sup | - |
dc.contributor.alternativeName | Lee, Dong Ki | - |
dc.contributor.alternativeName | Lee, Se Joon | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Chung, Jae Bock | - |
dc.contributor.alternativeName | Cho, Jae Yong | - |
dc.contributor.affiliatedAuthor | 박미숙 | - |
dc.contributor.affiliatedAuthor | 장양수 | - |
dc.citation.volume | 104 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2753 | - |
dc.citation.endPage | 2758 | - |
dc.identifier.bibliographicCitation | CANCER, Vol.104(12) : 2753-2758, 2005 | - |
dc.date.modified | 2017-05-04 | - |
dc.identifier.rimsid | 43961 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.